Literature DB >> 6450621

Proliferation, differentiation, and cytogenetics of chronic leukemic B lymphocytes cultured with mitomycin-treated normal cells.

P Nowell, T V Shankey, J Finan, D Guerry, E Besa.   

Abstract

Lymphocytes from 6 patients with chronic lymphocytic leukemia of the B-cell variety (B-CLL) were cultured with equal numbers of mitomycin-treated mononuclear cells from normal blood. When stimulated with pokeweed mitogen (PWM), phytohemagglutinin (PHA), or the tumor-promoting agent, phorbol tetradecanoyl-acetate (TPA), the CLL cells proliferated actively by day 3 or 4 of culture, and in four cases, differentiated to significant numbers of immunoglobulin-containing cells. Chromosome studies on the proliferating lymphocytes demonstrated a cytogenetically abnormal clone in three patients, including two with a 14q+ marker chromosome and two with a translocation involving the short arm of chromosome 9. One patient had a translocation from 22q to 14q, producing a Philadelphia chromosome as well as the 14q+ marker. The results indicate that the neoplastic lymphocytes of B-CLL may proliferate and differentiate when appropriately stimulated in vitro, and that chromosomally abnormal clones are not uncommon. With several techniques now available for successful short-term culture of B-CLL lymphocytes, there is opportunity for better understanding of the cellular alterations in this disease.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6450621

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

1.  bcl-1 rearrangement. Frequency and clinical significance among B-cell chronic lymphocytic leukemias and non-Hodgkin's lymphomas.

Authors:  E Athan; D R Foitl; D M Knowles
Journal:  Am J Pathol       Date:  1991-03       Impact factor: 4.307

2.  Functional and phenotypic heterogeneity of electrophoretically separated leukaemic B cells from patients with chronic lymphocytic leukaemia.

Authors:  C D Platsoucas
Journal:  Clin Exp Immunol       Date:  1985-06       Impact factor: 4.330

3.  PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma.

Authors:  C L Rosenberg; E Wong; E M Petty; A E Bale; Y Tsujimoto; N L Harris; A Arnold
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

4.  The chromosome 14 breakpoint in neoplastic B cells with the t(11;14) translocation involves the immunoglobulin heavy chain locus.

Authors:  J Erikson; J Finan; Y Tsujimoto; P C Nowell; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

5.  Phorbol ester induction of leukemic cell differentiation is a membrane-mediated process.

Authors:  R A Cooper; A D Braunwald; A L Kuo
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

6.  Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma.

Authors:  Y Tsujimoto; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

7.  12-O-Tetradecanoylphorbol-13-acetate (TPA) directly inhibits spontaneous immunoglobulin secretion by in vivo antigen-induced human lymphoblastoid B cells.

Authors:  J A Brieva; J S Louie; R H Stevens
Journal:  J Clin Immunol       Date:  1984-07       Impact factor: 8.317

8.  Mitogenic stimulation of malignant B cells. Chronic lymphocytic leukaemia: relationship between stimulation and surface phenotype.

Authors:  A C Bloem; E J Bast; F H Gmelig Meyling; G C DeGast; R E Ballieux
Journal:  Clin Exp Immunol       Date:  1982-11       Impact factor: 4.330

Review 9.  DNA rearrangements in human B- and T-cell malignancies.

Authors:  C I Smith; L Hammarström
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

10.  The human Vpre B gene is located on chromosome 22 near a cluster of V lambda gene segments.

Authors:  S R Bauer; K Huebner; M Budarf; J Finan; J Erikson; B S Emanuel; P C Nowell; C M Croce; F Melchers
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.